Hostname: page-component-77c89778f8-gvh9x Total loading time: 0 Render date: 2024-07-19T10:01:21.408Z Has data issue: false hasContentIssue false

Acute dystonic reaction following treatment with a non-classic neuroleptic of the dibenzazepine-type

Published online by Cambridge University Press:  28 April 2020

E. Scholz*
Affiliation:
Department of Neurology, University of Tübingen
K. Mann
Affiliation:
Department of Psychiatry, University of Tübingen
H.W. Schied
Affiliation:
Department of Psychiatry, University of Tübingen
M. Bartels
Affiliation:
Department of Psychiatry, University of Tübingen
*
Reprint requests to: Demande de tirés à part au : Dr. E. Scholz Department of Neurology, University of Tübingen, Liebermeisterstr. 18-20, D-7400 Tübingen
Get access

Summary

Extrapyramidal side-effects with drug-induced parkinsonism have not previously been reported following treatment with the atypical dibenzazepine-type neuroleptics, clozapine and fluperlapine. We have however observed reversible acute dystonia in a patient following high-dose fluperlapine treatment. The clinical signs of a discrete infantile cerebral palsy observed in our patient are probably one of the risk factors. Although the differential diagnosis of acute dystonia as opposed to tardive dyskinesia was difficult, the patient's symptoms fit more closely the former. Pharmacological aspects of the observed movement disorder are discussed.

Résumé

Résumé

Les effets secondaires de type extra-pyramidal pseudo-parkinsonien occasionnés par la clozapine et la fluperlapine, des neuroleptiques atypiques de type dibenzazépine, n’ont jusqu’à maintenant jamais été rapportes. Pourtant nous avons observé une dystonie réversible chez un patient dont le traitement était constitué de fortes doses de fluperlapine. Les signes d’une discrète parésie cérébrale de l’enfance, observés chez notre patient, constituent probablement l'un des facteurs de risque. Bien que le diagnostic différentiel entre la dystonie aiguë et la dyskinésie tardive ait été difficile à établir, les symptômes du patient correspondaient davantage à la première de ces hypothèses. Les implications pharmacologiques du trouble moteur que nous avons observé sont discutés.

Type
Articles Courts/Short Communications
Copyright
Copyright © European Psychiatric Association 1987

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

References/Bibliographie

Anden, N.E. - Animal models of the brain dopamine function. In: Birkmayer, W., Hornykiewicz, O. eds.: Advances in Parkinsonism, 169-177, Editions Roche, Basle, 1976.Google Scholar
Bartels, M., Themelis, J. - Computerized tomography in tardive dyskinesia. Evidence of structural abnormalities in the basal ganglia. Arch Psychiatr Nervenkr 1983; 233: 371379.CrossRefGoogle ScholarPubMed
Berzewski, H ., Helmchen, H., Hippius, H ., Hoffmann, H ., Kanowski, S. - Das klinische Wirkungsspektrum eines neuen Dibenzodiazepin-Derivates. Arzneim - Forsch /Drug res 1969; 19: 495496.Google Scholar
Buerki, H.R., Ruch, W., Asper, H. - Effects of clozapine, thioridazine, perlapine and haloperidol on the metabolism of the biogenic amines in the brain of the rat. Psychopharmacology (Berlin) 1975; 41: 2733.CrossRefGoogle Scholar
Casey, D.E. - Tardive dyskinesia: reversible and irreversible. In: Casey, D.E., Chase, T.N., Christensen, A.V.,Gerlach, J. eds.: Dyskinesia. Research and treatment, 88-97, Springer, Berlin, New York, 1985.CrossRefGoogle Scholar
Crane, G.E. - Persistent dyskinesia. Br J Psychiatry 1973; 122: 395405.CrossRefGoogle ScholarPubMed
Eichenberger, E. - Pharmacology of fluperlapine compared with clozapine. Arzneim - Forsch / Drug res 1984; 34(I): 110113.Google ScholarPubMed
Ekbom, K., Lindholm, H., Ljungberg, L. - New dystonic syndrome associated with butyrophenone therapy. Z Neurol 1972; 202: 94103.Google ScholarPubMed
Fischer-Cornelssen, K., Ferner, U. - Ergebnisse europaeischer Multicenter-Doppelblindstudien mit Clozapin (Leponex)., In: Berner, P., Saletu, B. eds.: Clozapin. Symposium Wien07.06.76, 819, Pharmazeutika Wander, Wien 1976.Google Scholar
Fischer-Cornelssen, K.A. - Fluperlapine in 104 schizophrenic patients. Arzneim. - Forsch./Drug res. 1984; 34 (I): 125130.Google ScholarPubMed
Gerlach, J. - Tardive Dyskinesia, Laegeforeningens Forlag, Copenhagen, 1979.Google Scholar
Hitri, A., Weiner, W.J., Borison, R.L., Diamond, B.I., Nausieda, P.A., Klawans, H.L. - Dopamine binding following prolonged haloperidol pretreatment. Ann Neurol 1978; 3: 134140.CrossRefGoogle ScholarPubMed
Kane, J.M., Woerner, M., Lieberman, J. - Tardive dyskinesia: prevalenee, incidence, and risk factors. In: Casey, D.E., Chase, T.N., Christensen, A.V., Gerlach, J. eds.: Dyskinesia. Research and treatment, 7278, Springer, Berlin, New York, 1985.CrossRefGoogle Scholar
Mann, K., Bartels, M., Gaertner, H.J., Schied, H.W., Wagner, W., Heimann, H. - Differential effects of a new dibenzazepine neuroleptic compared with haloperidol. Pharmacopsychiatry 1987; 20: 155159.CrossRefGoogle Scholar
Marsden, C.D. - Is tardive dyskinesia a unique disorder? In: Casey, D.E., Chase, T.N., Christensen, A.V., Gerlach, J. eds.: Dyskinesia. Research and treatment, 6471, Springer, Berlin, New York, 1985.CrossRefGoogle Scholar
Marsden, C.D., Tarsy, D., Baldessarini, R.J. - Spontaneous and drug-induced movement disorders in psychotic patients. In: Benson, D.F., Blumer, D. eds.: Psychiatric aspects of neurologic disease, 219266, Grune and Stratton, New York,Google Scholar
Scholz, E., Dichgans, J. - Treatment of drug-induced exogenous psychosis in parkinsonism with elozapine and fluperlapine. Eur Arch Psychiatr Neurol Sci 1985; 235: 6064.CrossRefGoogle Scholar
Woggon, B., Angst, J., Bartels, M., Heinrich, K., Hippius, H, Koukou, M., Krebs, E.et al. - Antipsychotic efficacy of fluperlapine. Neuropsychobiology 1984; 11: 116120.CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.